- Home
- SPRO vs INO Comparison
SPRO vs INO Comparison
Compare SPRO & INO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- INO
- Stock Information
- Founded
- SPRO 2013
- INO 1979
- Country
- SPRO United States
- INO United States
- Employees
- SPRO N/A
- INO N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- INO Medical/Dental Instruments
- Sector
- SPRO Health Care
- INO Health Care
- Exchange
- SPRO Nasdaq
- INO Nasdaq
- Market Cap
- SPRO 128.9M
- INO 136.6M
- IPO Year
- SPRO 2017
- INO 1998
- Fundamental
- Price
- SPRO $2.36
- INO $2.42
- Analyst Decision
- SPRO Buy
- INO Buy
- Analyst Count
- SPRO 4
- INO 5
- Target Price
- SPRO $5.00
- INO $8.80
- AVG Volume (30 Days)
- SPRO 1.2M
- INO 1.1M
- Earning Date
- SPRO 11-13-2025
- INO 11-10-2025
- Dividend Yield
- SPRO N/A
- INO N/A
- EPS Growth
- SPRO N/A
- INO N/A
- EPS
- SPRO N/A
- INO N/A
- Revenue
- SPRO $48,576,000.00
- INO $182,337.00
- Revenue This Year
- SPRO N/A
- INO N/A
- Revenue Next Year
- SPRO N/A
- INO $14,751.49
- P/E Ratio
- SPRO N/A
- INO N/A
- Revenue Growth
- SPRO N/A
- INO N/A
- 52 Week Low
- SPRO $0.51
- INO $1.30
- 52 Week High
- SPRO $3.22
- INO $5.80
- Technical
- Relative Strength Index (RSI)
- SPRO 57.47
- INO 49.71
- Support Level
- SPRO $2.16
- INO $2.36
- Resistance Level
- SPRO $2.44
- INO $2.67
- Average True Range (ATR)
- SPRO 0.12
- INO 0.13
- MACD
- SPRO -0.00
- INO -0.01
- Stochastic Oscillator
- SPRO 55.24
- INO 37.72
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.